Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.
An Observational Cohort Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.
Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.
In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.
Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.
We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Uffici Studi FIL
- Numero di telefono: +390131033153
- Email: startup@filinf.it
Backup dei contatti dello studio
- Nome: Uffici Studi FIL
- Numero di telefono: +390599769913
- Email: gestionestudi@filinf.it
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.
Descrizione
Inclusion criteria:
General Inclusion Criteria:
- Histologically confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
- Age ≥ 18 years at the time of BTKi-based treatment initiation.
- Patients who are able to understand the nature and objectives of the study and who have provided written informed consent, approved by the Independent Ethics Committee (IEC), for participation in the observational study.
For the retrospective enrollment group:
In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:
● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.
For the prospective enrollment group:
In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:
● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.
Exclusion criteria:
- Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
- Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
- Inability or unwillingness to provide written informed consent, where required by applicable ethical and regulatory requirements.
- Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: CROSS_SECTIONAL
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
|---|
|
Retrospective enrollment group
Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96. |
|
Prospective enrollment group
Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Best overall response
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Progression-free survival (PFS)
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Overall survival (OS)
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Event-free survival (EFS)
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Time to next treatment (TTNT)
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to the initiation of a NALT. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Duration of response (DOR)
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Non-relapse mortality (NRM)
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as death without prior relapse or progression |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
POD24
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD) |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Incidence of adverse events
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Incidence of deaths
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any). |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Treatment duration
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Treatment discontinuation
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other). |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Treatment modifications
Lasso di tempo: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Frequency and reasons for dose reductions, interruptions and other modifications. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Marco Ladetto, MD, S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- FIL_MANTLE-FIRST-BTKi
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .